Preempting Lassa

How Kineta is aiming to stay one step ahead of Lassa fever

With the announcement of positive preclinical results for its Lassa fever compound in April and an award of up to £5 million ($6.7 million) from the Wellcome Trust in May, Kineta Inc. is aiming to get ahead of what could be the next major viral hemorrhagic fever outbreak in

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers